Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paychex, Inc. (PAYX) vs Pfizer Inc (PFE) Price & Performance

Paychex, Inc.Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Paychex, Inc. vs Pfizer Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $43.33B), while Pfizer Inc trades at $27.84 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 3.7× Paychex, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.

PAYXPFE
Market Cap
$43.33B$158.39B
Sector
IndustrialsHealth
52-Week High
$135.46$29.02
52-Week Low
$85.57$23.60
Enterprise Value
$46.81B$209.89B
Dividend Yield
3.91%6.19%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paychex, Inc.

Paychex (PAYX) trades at $116.93, down 3.93% over the past day, near the consensus price target of $118.17. The stock shows strong profitability with a 27.03% net income margin and 44.77% ROE, though valuation ratios like a P/E of 24.89 and P/S of 6.73 are elevated. Recent quarters have consistently beaten EPS estimates, and the company is advancing its AI-driven WISE platform to enhance payroll efficiency. Technical indicators are mixed, with a bearish moving average signal but an oversold RSI suggesting potential near-term support.

The outlook for PAYX is cautiously optimistic, supported by steady earnings beats and strategic AI integration, but high valuation and mixed analyst sentiment pose risks. Investment opportunity lies in continued execution on margin expansion and market share gains in HR solutions, while key risks include competitive pressures and economic sensitivity affecting small business clients.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE